Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics
New York, USA, July 16, 2025 (GLOBE NEWSWIRE) — Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics | DelveInsight
The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT), AI-powered applications, and smart wearables are transforming the diagnostic landscape by making it more accessible and user-friendly. These innovations not only reduce the dependency on traditional sleep labs but also facilitate earlier diagnosis and timely intervention. As a result, more patients are entering the treatment pathway, supporting both improved clinical outcomes and sustained market expansion.
DelveInsight's 'Obstructive Sleep Apnea Pipeline Insight 2025' report provides comprehensive global coverage of pipeline obstructive sleep apnea therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obstructive sleep apnea pipeline domain.
Key Takeaways from the Obstructive Sleep Apnea Pipeline Report DelveInsight's obstructive sleep apnea pipeline report depicts a robust space with 12+ active players working to develop 14+ pipeline obstructive sleep apnea drugs.
active players working to develop pipeline obstructive sleep apnea drugs. Key obstructive sleep apnea companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science , and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape.
and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape. Promising pipeline obstructive sleep apnea therapies, such as Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others, are in different phases of obstructive sleep apnea clinical trials.
and others, are in different phases of obstructive sleep apnea clinical trials. In June 2025 , Innovent Biologics, Inc. announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of Mazdutide , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2).
, announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with and obesity (BMI ≥ 28 kg/m2). In April 202 5, Apnimed announced that the first patient had been dosed in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, SASS-001 , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi).
5, announced that the in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi). In April 2025 , Shionogi & Co., Ltd. announced that it had entered into an agreement with Apnimed, Inc. for the introduction of sulthiame * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed.
, Shionogi & Co., Ltd. announced that it had entered into an with for the introduction of * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed. In April 2025 , Apnimed announced that it had acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame , a differentiated carbonic anhydrase inhibitor, in the broad field of sleep apnea and sleep-related breathing diseases, from D esitin Arzneimittel GmbH . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS).
, announced that it had to develop and commercialize , a differentiated carbonic anhydrase inhibitor, in the broad field of and sleep-related breathing diseases, from D . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS). In April 2025 , Incannex Healthcare Inc. announced that the Company has completed Phase II patient enrollment in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.
, announced that the Company has in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality. In January 2025, Mineralys Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had cleared the Company's Investigational New Drug (IND) Application for a Phase II clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.
Request a sample and discover the recent advances in obstructive sleep apnea drugs @ Obstructive Sleep Apnea Pipeline Report
The obstructive sleep apnea pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Obstructive Sleep Apnea drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obstructive sleep apnea clinical trial landscape.
Obstructive Sleep Apnea Overview
Obstructive sleep apnea (OSA) is a sleep disorder marked by repeated episodes of partial or complete blockage of the upper airway during sleep. These episodes cause drops in oxygen levels and frequent awakenings, resulting in fragmented, poor-quality sleep. Common signs include loud snoring, witnessed pauses in breathing, and excessive daytime sleepiness. OSA can have wide-ranging health effects, impairing cardiovascular health, behavior, quality of life, and even driving safety. While other types of sleep-disordered breathing, such as central sleep apnea, upper airway resistance syndrome, and obesity hypoventilation, share some features with OSA, they are distinct conditions and will be discussed separately.
The symptoms of OSA vary and can severely impact day-to-day functioning. These include persistent daytime drowsiness, loud snoring, gasping or choking during sleep, morning headaches, dry mouth or sore throat upon waking, difficulty concentrating, mood disturbances such as irritability or depression, high blood pressure, and reduced libido. These manifestations can greatly affect both physical well-being and overall life quality.
The underlying cause of OSA involves upper airway obstruction during sleep, mainly due to negative pressure that causes the airway to collapse during inhalation. A key area of concern is the narrowing of the airway in the retropalatal region during exhalation. Obesity is a significant risk factor, with a higher body mass index (BMI) linked to greater airway narrowing. Both structural factors (like airway size) and neuromuscular control contribute to this condition. Understanding how airflow interacts with pressure in collapsible airways is vital to grasping the mechanics of OSA. Additional anatomical and physiological factors also influence the severity of the disorder.
Managing OSA requires a personalized and multifaceted approach. For mild-to-moderate cases, lifestyle changes, such as losing weight, maintaining good sleep habits, and avoiding alcohol and sedatives, are important first steps. Continuous positive airway pressure (CPAP) therapy is the most effective treatment for moderate-to-severe OSA, though adherence can be difficult. Alternatives like oral appliances, especially mandibular advancement devices, may help in less severe cases. Surgical options, including uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (HNS), may be considered for more severe or treatment-resistant cases. In rare, severe situations, a tracheostomy may be necessary, particularly for patients with significant comorbidities. Ultimately, the best outcomes are achieved through an individualized treatment plan that may combine several strategies to relieve symptoms, improve sleep quality, and enhance overall health.
Find out more about obstructive sleep apnea drugs @ Obstructive Sleep Apnea Treatment
A snapshot of the Pipeline Obstructive Sleep Apnea Drugs mentioned in the report: Drugs Company Phase MoA RoA AD109 Apnimed III Adrenergic uptake inhibitors; Cholinergic receptor antagonists; Muscarinic receptor antagonists Oral Retatrutide Eli Lilly and Company III Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists Subcutaneous IHL-42X Incannex Healthcare Ltd II/III Cannabinoid receptor CB2 agonists; Carbonic anhydrase inhibitors Oral Lorundrostat Mineralys Therapeutics Inc. II Aldosterone synthase inhibitors Oral Sulthiame Apnimed II Carbonic anhydrase inhibitors Oral SASS-001 Shionogi Apnimed Sleep Science II Purinergic P2X3 receptor antagonists Oral
Learn more about the emerging obstructive sleep apnea therapies @ Obstructive Sleep Apnea Clinical Trials
Obstructive Sleep Apnea Therapeutics Assessment
The obstructive sleep apnea pipeline report proffers an integral view of the emerging obstructive sleep apnea therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Obstructive Sleep Apnea Pipeline Report Coverage : Global
: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists
: Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists Key Obstructive Sleep Apnea Companies : Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others.
: Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others. Key Obstructive Sleep Apnea Pipeline Therapies: Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others.
Dive deep into rich insights for new obstructive sleep apnea treatments, visit @ Obstructive Sleep Apnea Drugs
Table of Contents 1. Obstructive Sleep Apnea Pipeline Report Introduction 2. Obstructive Sleep Apnea Pipeline Report Executive Summary 3. Obstructive Sleep Apnea Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Obstructive Sleep Apnea Clinical Trial Therapeutics 6. Obstructive Sleep Apnea Pipeline: Late-Stage Products (Pre-registration) 7. Obstructive Sleep Apnea Pipeline: Late-Stage Products (Phase III) 8. Obstructive Sleep Apnea Pipeline: Mid-Stage Products (Phase II) 9. Obstructive Sleep Apnea Pipeline: Early-Stage Products (Phase I) 10. Obstructive Sleep Apnea Pipeline Therapeutics Assessment 11. Inactive Products in the Obstructive Sleep Apnea Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Obstructive Sleep Apnea Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix
For further information on the obstructive sleep apnea pipeline therapeutics, reach out @ Obstructive Sleep Apnea Therapeutics
Related Reports
Obstructive Sleep Apnea Epidemiology Forecast
Obstructive Sleep Apnea Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted obstructive sleep apnea epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Obstructive Sleep Apnea Market
Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., among others.
Sleep Apnea Market
Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others.
Sleep Apnea Pipeline
Sleep Apnea Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others.
Sleep Apnea Diagnostic Devices Market
Sleep Apnea Diagnostic Devices Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea diagnostic devices companies, including Natus Medical Incorporated., SOMNOmedics GmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited., ActiGraph, LLC., Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A., among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
40 minutes ago
- Business Upturn
Craig Harper Fights Cancer with Single-Digit Body Fat and a 'Be Savage' Mindset on Health is a Skill with Todd Vande Hei
By GlobeNewswire Published on July 25, 2025, 02:56 IST Beverly Hills California, July 24, 2025 (GLOBE NEWSWIRE) — In an episode that redefines resilience, Todd Vande Hei, CEO of Stark and host of Health is a Skill , sits down with 61-year-old executive Craig Harper to explore how deliberate health optimization can become a powerful edge against disease. Diagnosed with multiple myeloma, an incurable blood cancer, Harper was told by his first oncologist there was 'nothing he could do.' Instead, he chose to rewrite the script. 'I'd rather be a warrior in a garden than a gardener in a war,' Harper said. Instead of waiting passively for chemo, he doubled down on proactive labs, heavy lifting, and long weighted walks. Today, he maintains just 9% body fat, logs 15,000 steps daily in a 40-pound vest, and surfs whenever possible, remarkably with no current symptoms. Highlights from their conversation included: Why Stark's routine lab work caught his cancer early, enabling a critical head start on intervention. How building lean mass and metabolic flexibility became essential tools, with muscle acting as 'storage for sugar'—helping to undercut cancer's fuel. The role of sauna, nasal breathing, and mobility in keeping him hiking strenuous trails and popping up on a surfboard at 61. Teaching his grandkids to 'be savage, not average,' encouraging them to find and test their own edges in life. Reflecting on the typical American path, Harper added, 'So many of my counterparts just seek comfort, too much alcohol, junk food, the couch. It seems like pleasure, but it leads to misery.' Instead, he hopes his story inspires others to take control before a diagnosis forces the issue. 'When the old man's knocking, don't let him in,' he advised. Listeners can hear the full episode on Spotify, Apple Podcasts, and YouTube. To explore how personalized strength, nutrition, and lab analysis can help build a more resilient body, visit About Health Is a Skill Health is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark. Each episode blends scientific insight, personal stories, and actionable habits to show how optimizing healthspan can transform every decade of life. Media Communications [email protected] Attachment Craig Harper shares how he's out-training blood cancer with Todd Vande Hei on Health is a Skill. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
40 minutes ago
- Business Upturn
Happy Mindset Inc. Survey Reveals 64% of U.S. and Canadian Respondents Feel Stuck in Progress Toward Goals, Experiencing Significant Emotional Impact
Waterloo, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Happy Mindset Inc., a company that supports high-achieving individuals by helping them identify and shift mindset constraints that block progress toward their goals, today announced results from its inaugural State of Feeling Stuck survey. The survey reveals not only how widespread feeling stuck is but also the significant emotional toll and the types of support people need to move forward. The study, conducted with 350 respondents across the United States and Canada, reveals that 87% reported feeling stuck at some point in the past three months, with 64% currently feeling stuck at the time of response. This highlights a widespread and ongoing challenge among North Americans. The survey defined feeling stuck as having a goal important to one's happiness but lacking clarity on how to make meaningful progress, or sensing that their actions were not moving them closer to that goal. Respondents making steady progress or without specific goals were considered not stuck. Respondents who indicated that they felt stuck were asked which areas of their lives they felt stuck in and could select multiple options. The three most commonly selected areas were career or work (59%), finances (55%), and health and wellness (40%). Many selected multiple areas; in fact, 72% reported feeling stuck in more than one part of their lives. The survey also reveals the significant emotional toll feeling stuck takes on individuals. Respondents who reported being stuck in the past three months were asked how feeling stuck affected their daily lives: 73% said feeling stuck increased their stress or anxiety 67% said feeling stuck decreased their motivation 60% said feeling stuck made them feel overwhelmed 56% said feeling stuck affected their mood For some, this experience is not short-lived. Thirty-four percent (34%) of all respondents said they had felt stuck for six months or longer. This suggests that for many, feeling stuck is not only emotionally difficult but also persistent, with potential impacts on long-term well-being and daily functioning. Building on these insights, the survey also explored what forms of support participants found most helpful in overcoming feeling stuck. Both individuals who have successfully navigated these challenges and those currently experiencing them emphasized the value of personalized, connected assistance, in three key themes: Someone to talk to who can help think through challenges Clarity on the reasons behind feeling stuck New ideas not previously considered Reflecting on these findings, Dr. Ada Y. Barlatt, Founder of Happy Mindset Inc., shares her perspective: 'Even though we often feel like we're stuck alone, this survey shows just how common the experience of feeling stuck really is and how deeply it impacts our lives. It highlights the need for practical, personalized ways to shift their mindset and perspective to regain momentum.' The study provides a valuable baseline for continued exploration and tailored solutions for individuals and organizations that are feeling stuck. A follow-up survey is planned for next quarter. About Happy Mindset Inc. Happy Mindset Inc., based in Waterloo, Ontario, Canada, uses its Mindset Engineering method to guide clients in clarifying their goals using necessary and sufficient conditions, uncovering mindset constraints, and integrating well-engineered affirmations into daily life, empowering steady, meaningful progress. At its core, Happy Mindset offers a supportive path grounded in both empathy and precision that is designed to help clients move from feeling stuck to clarity and real momentum. Individuals can start their journey to getting unstuck at For select highlights from the survey, including confidence intervals, methodology and questions with notable U.S. and Canadian differences, visit Happy Mindset Inc. invites media inquiries and interviews to explore these findings in greater detail and explore how mindset engineering is helping people get unstuck in work and life. Media Contact: Dr. Ada Y. Barlatt, Engineer | FounderHappy Mindset Inc. [email protected]
Yahoo
3 hours ago
- Yahoo
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or +1-412-232-3651 (from other countries) IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it conducted a Special Meeting of Stockholders and partially adjourned the meeting for Proposal 2, the proposal to approve the sale of substantially all of ReShape's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (Asset Sale Proposal), and Proposal 3, the proposal to approve and adopt proposed amendments to ReShape's certificate of incorporation in connection with ReShape's proposed merger (Merger) with Vyome Therapeutics, Inc. (Charter Amendment Proposal). All other proposals required for the Merger were approved by stockholders. ReShape adjourned the Special Meeting of Stockholders with respect to the Asset Sale Proposal and Charter Amendment Proposal to allow additional time to solicit proxies with respect to these proposals. Approval of the Asset Sale Proposal and the Charter Amendment Proposal are conditions to the consummation of the Merger. Addressing the Company's stockholders, Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, noted, 'Our ability to complete the Merger, which we believe will maximize value for our stockholders, is contingent upon approval of the Asset Sale Proposal and the Charter Amendment Proposal. Your vote for the Asset Sale Proposal is key to the Merger, and your vote for the Charter Amendment Proposal is important for the operation of the combined company following the Merger.' The Special Meeting of Stockholders will resume with respect to the Asset Sale Proposal and the Charter Amendment Proposal on Thursday, August 7, 2025 at 11:30 a.m. Eastern Time. The reconvened meeting will be held virtually at The record date for determining stockholders eligible to vote at the Special Meeting of Stockholders remains the same, June 9, 2025. ReShape encourages all stockholders of record as of June 9, 2025 that have not yet submitted proxies to submit proxies in favor of the Asset Sale Proposal and the Charter Amendment Proposal and to do so promptly. Those who voted against these proposals are asked to please reconsider their votes based on the factors described in this press release. The proxy statement for the Special Meeting of Stockholders of ReShape filed on June 24, 2025 contains important information, and this press release should be read in conjunction with the proxy statement, which, along with other relevant materials, is available at no charge at the U.S. Securities and Exchange Commission's website and at the Company's website YOUR VOTE IS VERY IMPORTANT!Stockholders can vote by telephone, or via the follow the easy instructions on the proxy card or voting instruction form previously sent. For any questions or assistance in voting shares, please call our proxy solicitor, INNISFREE M&A INCORPORATEDTOLL-FREE, at 1-877-750-8310 (from the U.S. and Canada)or +1-412-232-3651 (from other countries) About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immune-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. Based in Cambridge, MA, the company has announced its intent to be listed on the Nasdaq exchange under the ticker 'HIND' pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) in early 2025. To learn more, please visit About Biorad MedisysBiorad Medisys Pvt. Ltd.® is a rapidly growing med-tech company dedicated to redefining healthcare standards with precision-engineered medical devices backed by rigorous scientific research. It operates three business units – Indovasive, Orthovasive and Neurovasive. Indovasive offers consumables and equipment in Urology and Gastroenterology. The Orthovasive segment sells a complete range of Knee and Hip implants for both Primary and Revision surgeries. It has recently forayed into Neurovascular BU for selling a wide portfolio of products in peripheral vascular, neurovascular and rehabilitation segments. It has two manufacturing facilities in India and is currently exporting to 50+ countries. To realize its global expansion strategy, it recently acquired a Swiss based company, Marflow, which specializes in commercialization of products in Urology & Gastroenterology. About ReShape Lifesciences® ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit Forward-Looking Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. Additional InformationIn connection with the proposed Merger and sale of assets to Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd. (Asset Sale), ReShape filed with the SEC on June 24, 2025 and mailed or otherwise provided to its stockholders the joint proxy statement/prospectus (joint proxy statement/prospectus) and other relevant documents in connection with the proposed Merger and Asset Sale. Before making a voting decision, ReShape's stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed Merger and Asset Sale or incorporated by reference therein carefully and in their entirety because they contain important information about ReShape, Vyome and the proposed transactions. Investors and stockholders may obtain a free copy of these materials and other documents filed by ReShape with the SEC at the SEC's website at at ReShape's website at or by sending a written request to ReShape at 18 Technology Drive, Suite 110, Irvine, California 92618, Attention: Corporate Secretary. CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
